{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T21:53:48Z","timestamp":1772142828156,"version":"3.50.1"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The coronavirus disease 2019 (COVID-19) becomes a worldwide public health threat. Increasing evidence proves that COVID-19-induced acute injuries could be reversed by a couple of therapies. After that, post-COVID-19 fibrosis (PCF), a sequela of \u201cLong COVID,\u201d earns rapidly emerging concerns. PCF is associated with deteriorative lung function and worse quality of life. But the process of PCF remains speculative. Therefore, we aim to conduct a bibliometric analysis to explore the overall structure, hotspots, and trend topics of PCF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>A comprehensive search was performed in the Web of Science core database to collect literature on PCF. Search syntax included COVID-19 relevant terms: \u201cCOVID 19,\u201d \u201cCOVID-19 Virus Disease,\u201d \u201cCOVID-19 Virus Infection,\u201d \u201cCoronavirus Disease-19,\u201d \u201c2019 Novel Coronavirus Disease,\u201d \u201c2019 Novel Coronavirus Infection,\u201d \u201cSARS Coronavirus 2 Infection,\u201d \u201cCOVID-19 Pandemic,\u201d \u201cCoronavirus,\u201d \u201c2019-nCoV,\u201d and \u201cSARS-CoV-2\u201d; and fibrosis relevant terms: \u201cFibrosis,\u201d \u201cFibroses,\u201d and \u201cCirrhosis.\u201d Articles in English were included. Totally 1,088 publications were enrolled. Searching results were subsequentially exported and collected for the bibliometric analysis. National, organizational, and individual level data were analyzed and visualized through biblioshiny package in the R, VOSviewer software, the CiteSpace software, and the Graphical Clustering Toolkit (gCLUTO) software, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The intrinsic structure and development in the field of PCF were investigated in the present bibliometric analysis. The topmost keywords were \u201cCOVID-19\u201d (occurrences, 636) surrounded by \u201cSARS-CoV-2\u201d (occurrences, 242), \u201ccoronavirus\u201d (occurrences, 123), \u201cfibrosis\u201d (occurrences, 120), and \u201cpneumonia\u201d (occurrences, 94). The epidemiology, physiopathology, diagnosis, and therapy of PCF were extensively studied. After this, based on dynamic analysis of keywords, hot topics sharply changed from \u201cWuhan,\u201d \u201cinflammation,\u201d and \u201ccytokine storm\u201d to \u201cquality of life\u201d and \u201cinfection\u201d through burst detection; from \u201cacute respiratory syndrome,\u201d \u201ccystic-fibrosis\u201d and \u201cfibrosis\u201d to \u201cinfection,\u201d \u201cCOVID-19,\u201d \u201cquality-of-life\u201d through thematic evolution; from \u201cenzyme\u201d to \u201cpost COVID.\u201d Similarly, co-cited references analysis showed that topics of references with most citations shift from \u201cpulmonary pathology\u201d (cluster 0) to \u201cCOVID-19 vaccination\u201d (cluster 6). Additionally, the overview of contributors, impact, and collaboration was revealed. Summarily, the USA stood out as the most prolific, influential, and collaborative country. The Udice French Research University, Imperial College London, Harvard University, and the University of Washington represented the largest volume of publications, citations, <jats:italic>H<\/jats:italic>-index, and co-authorships, respectively. Dana Albon was the most productive and cited author with the strongest co-authorship link strength. <jats:italic>Journal of Cystic Fibrosis<\/jats:italic> topped the list of prolific and influential journals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Outcomes gained from this study assisted professionals in better realizing PCF and would guide future practices. Epidemiology, pathogenesis, and therapeutics were study hotspots in the early phase of PCF research. As the spread of the COVID-19 pandemic and progress in this field, recent attention shifted to the quality of life of patients and post-COVID comorbidities. Nevertheless, COVID-19 relevant infection and vaccination were speculated to be research trends with current and future interest. International cooperation as well as in-depth laboratory experiments were encouraged to promote further explorations in the field of PCF.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2022.967829","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T05:31:12Z","timestamp":1663651872000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Scars of COVID-19: A bibliometric analysis of post-COVID-19 fibrosis"],"prefix":"10.3389","volume":"10","author":[{"given":"Han","family":"Zhong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Ya","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ri","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Hua","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng-Yu","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiao-Yi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun-Peng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,20]]},"reference":[{"key":"B1","unstructured":""},{"key":"B2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.cytogfr.2020.04.002","article-title":"Cytokine storm intervention in the early stages of COVID-19 pneumonia","volume":"53","author":"Sun","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"B3","article-title":"The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors","volume-title":"Clin Chem Lab Med.","author":"Vianello","year":"2021"},{"key":"B4","doi-asserted-by":"crossref","first-page":"m3379","DOI":"10.1136\/bmj.m3379","article-title":"A living WHO guideline on drugs for COVID-19","volume":"370","author":"Agarwal","year":"2020","journal-title":"BMJ."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2100048","DOI":"10.1183\/13993003.00048-2021","article-title":"Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline","volume":"57","author":"Chalmers","year":"2021","journal-title":"Eur Respir J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3390\/jcm10112452","article-title":"Post-COVID-19 pulmonary fibrosis: novel sequelae of the current pandemic","volume":"10","author":"Ambardar","year":"2021","journal-title":"J Clin Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"A393","DOI":"10.1016\/j.chest.2021.07.393","article-title":"Giraffe in the COVID-19 lung: pulmonary fibrosis limiting severity of the pneumothorax","volume":"160","author":"Allen Chan","year":"2021","journal-title":"Chest."},{"key":"B8","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41575-021-00426-4","article-title":"COVID-19 and liver disease: mechanistic and clinical perspectives","volume":"18","author":"Marjot","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S2213-2600(20)30225-3","article-title":"Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy","volume":"8","author":"George","year":"2020","journal-title":"Lancet Resp Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"E55","DOI":"10.1148\/radiol.2020200843","article-title":"Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: a longitudinal study","volume":"296","author":"Wang","year":"2020","journal-title":"Radiology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2001217","DOI":"10.1183\/13993003.01217-2020","article-title":"Abnormal pulmonary function in COVID-19 patients at time of hospital discharge","volume":"55","author":"Mo","year":"2020","journal-title":"Eur Respir J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/qjmed\/hcaa255","article-title":"Post-COVID-19 pneumonia pulmonary fibrosis","volume":"113","author":"Tale","year":"2020","journal-title":"QJM."},{"key":"B13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S2213-2600(13)70053-5","article-title":"Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: a prospective cohort study of clinical autopsies","volume":"1","author":"Thille","year":"2013","journal-title":"Lancet Resp Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/thoraxjnl-2020-216086","article-title":"Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort","volume":"76","author":"Arnold","year":"2021","journal-title":"Thorax."},{"key":"B15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.trsl.2021.09.001","article-title":"From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic?","volume":"241","author":"Michalski","year":"2022","journal-title":"Transl Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of fibrotic lung diseases","volume":"383","author":"Wijsenbeek","year":"2020","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"8793","DOI":"10.3390\/ijms21228793","article-title":"Endothelial damage in acute respiratory distress syndrome","volume":"21","author":"Vassiliou","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"6120","DOI":"10.18632\/aging.103010","article-title":"Alveolar macrophage\u2014derived exosomes modulate severity and outcome of acute lung injury","volume":"12","author":"Ye","year":"2020","journal-title":"Aging."},{"key":"B19","doi-asserted-by":"publisher","first-page":"599502","DOI":"10.3389\/fonc.2020.599502","article-title":"COVID-19: high-JAKing of the inflammatory \u201cflight\u201d by ruxolitinib to avoid the cytokine storm","volume":"10","author":"Botta","year":"2020","journal-title":"Front Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1164\/rccm.202005-1583OC","article-title":"Characterization of the inflammatory response to severe COVID-19 illness","volume":"202","author":"McElvaney","year":"2020","journal-title":"Am J Respir Crit Care Med."},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00182-17","article-title":"Overactive epidermal growth factor receptor signaling leads to increased fibrosis after severe acute respiratory syndrome coronavirus infection","volume-title":"J Virol.","author":"Venkataraman","year":"2017"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.928996","article-title":"Long-term respiratory and neurological sequelae of COVID-19","volume-title":"Med Sci Monitor.","author":"Wang","year":"2020"},{"key":"B23","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41591-021-01283-z","article-title":"Post-acute COVID-19 syndrome","volume":"27","author":"Nalbandian","year":"2021","journal-title":"Nat Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S0140-6736(20)32656-8","article-title":"6-month consequences of COVID-19 in patients discharged from hospital: a cohort study","volume":"397","author":"Huang","year":"2021","journal-title":"Lancet."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/thoraxjnl-2020-215314","article-title":"Respiratory follow-up of patients with COVID-19 pneumonia","volume":"75","author":"George","year":"2020","journal-title":"Thorax."},{"key":"B26","doi-asserted-by":"publisher","first-page":"109017","DOI":"10.1016\/j.ejrad.2020.109017","article-title":"Early CT features and temporal lung changes in COVID-19 pneumonia in Wuhan, China","volume":"128","author":"Hu","year":"2020","journal-title":"Eur J Radiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/his.14249","article-title":"Progression to fibrosing diffuse alveolar damage in a series of 30 minimally invasive autopsies with COVID-19 pneumonia in Wuhan, China","volume":"78","author":"Li","year":"2021","journal-title":"Histopathology."},{"key":"B28","doi-asserted-by":"publisher","first-page":"9057","DOI":"10.21037\/apm-21-1836","article-title":"Global research hotspots and research trends on idiopathic pulmonary fibrosis: a bibliometric and visualization analysis","volume":"10","author":"Ma","year":"2021","journal-title":"Ann Palliat Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.rxeng.2021.01.002","article-title":"Bibliometric indicators to evaluate scientific activity","volume":"63","author":"Garc\u00eda-Villar","year":"2021","journal-title":"Radiolog"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/jamia\/ocaa107","article-title":"Mapping scientific landscapes in UMLS research: a scientometric review","volume":"27","author":"Kim","year":"2020","journal-title":"J Am Med Inform Assoc."},{"key":"B31","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.engappai.2018.11.007","article-title":"Industry 4.0: a bibliometric analysis and detailed overview","volume":"78","author":"Muhuri","year":"2019","journal-title":"Eng Appl Artif Intell."},{"key":"B32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/DSS.0000000000003251","article-title":"Merkel cell carcinoma: a bibliometric analysis of the top 100 cited publications","volume":"48","author":"Russomanno","year":"2022","journal-title":"Dermatol Surg."},{"key":"B33","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.joi.2017.08.007","article-title":"bibliometrix: An R-tool for comprehensive science mapping analysis","volume":"11","author":"Aria","year":"2017","journal-title":"J Informetr."},{"key":"B34","doi-asserted-by":"publisher","first-page":"5303","DOI":"10.1073\/pnas.0307513100","article-title":"Searching for intellectual turning points: progressive knowledge domain visualization","volume":"101","author":"Chen","year":"2004","journal-title":"Proc Natl Acad Sci USA."},{"key":"B35","doi-asserted-by":"publisher","first-page":"20","DOI":"10.47176\/mjiri.35.20","article-title":"COVID-19 research progress: Bibliometrics and visualization analysis","volume":"35","author":"Okhovati","year":"2021","journal-title":"Med J Islam Repub Iran."},{"key":"B36","doi-asserted-by":"publisher","first-page":"5088129","DOI":"10.1155\/2021\/5088129","article-title":"Research status quo in traditional Mongolian medicine: a bibliometric analysis on research documents in the web of science database","volume":"2021","author":"Kim","year":"2021","journal-title":"Evid Based Complement Alternat Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12885-021-07818-4","article-title":"A 10-year bibliometric analysis of osteosarcoma and cure from 2010 to 2019","volume":"21","author":"Da","year":"2021","journal-title":"BMC Cancer."},{"key":"B38","doi-asserted-by":"publisher","first-page":"6175964","DOI":"10.1155\/2020\/6175964","article-title":"Pulmonary fibrosis in COVID-19 survivors: predictive factors and risk reduction strategies","volume":"2020","author":"Ojo","year":"2020","journal-title":"Pulm Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"L257","DOI":"10.1152\/ajplung.00238.2020","article-title":"Healing after COVID-19: are survivors at risk for pulmonary fibrosis?","volume":"320","author":"McDonald","year":"2021","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S2213-2600(20)30222-8","article-title":"Pulmonary fibrosis secondary to COVID-19: a call to arms?","volume":"8","author":"Spagnolo","year":"2020","journal-title":"Lancet Resp Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.2147\/TCRM.S275779","article-title":"A dangerous consequence of the recent pandemic: early lung fibrosis following COVID-19 pneumonia\u2014case reports","volume":"16","author":"Scelfo","year":"2020","journal-title":"Therap Clin Risk Manag."},{"key":"B42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/ALN.0000000000000264","article-title":"Mechanical ventilation-associated lung fibrosis in acute respiratory distress syndrome: a significant contributor to poor outcome","volume":"121","author":"Cabrera-Benitez","year":"2014","journal-title":"Anesthesiology."},{"key":"B43","doi-asserted-by":"publisher","first-page":"110005","DOI":"10.1016\/j.mehy.2020.110005","article-title":"Pirfenidone: a novel hypothetical treatment for COVID-19","volume":"144","author":"Seifirad","year":"2020","journal-title":"Med Hypotheses."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e00744","DOI":"10.1002\/rcr2.744","article-title":"Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019","volume":"9","author":"Ogata","year":"2021","journal-title":"Respirol Case Rep."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e26705","DOI":"10.1097\/MD.0000000000026705","article-title":"Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: a single center experience from Pune, Western India","volume":"100","author":"Dravid","year":"2021","journal-title":"Medicine (Baltimore)."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e12939","DOI":"10.1111\/cpr.12939","article-title":"Stem cell therapy for COVID-19, ARDS and pulmonary fibrosis","volume":"53","author":"Li","year":"2020","journal-title":"Cell Prolif."},{"key":"B47","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/stem.3354","article-title":"Mesenchymal stem cell immunomodulation: in pursuit of controlling COVID-19 related cytokine storm","volume":"39","author":"Song","year":"2021","journal-title":"Stem Cells."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1097\/SLA.0000000000003955","article-title":"Lung transplantation for elderly patients with end-stage COVID-19 pneumonia","volume":"272","author":"Han","year":"2020","journal-title":"Ann Surg."},{"key":"B49","first-page":"233","article-title":"The management of pulmonary fibrosis in COVID-19","volume":"53","author":"Rumende","year":"2021","journal-title":"Acta Med Indones."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1080\/1744666X.2021.1847640","article-title":"Natural history of COVID-19 and therapeutic options","volume":"16","author":"Gautret","year":"2020","journal-title":"Expert Rev Clin Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-020-00334-0","article-title":"SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct Target Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet."},{"key":"B53","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cytogfr.2020.06.001","article-title":"SARS-CoV-2 infection: the role of cytokines in COVID-19 disease","volume":"54","author":"Costela-Ruiz","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"B54","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1513\/pats.200601-008AW","article-title":"Transforming growth factor beta: a central modulator of pulmonary and airway inflammation and fibrosis","volume":"3","author":"Sheppard","year":"2006","journal-title":"Proc Am Thorac Soc."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1902216","DOI":"10.1183\/13993003.02216-2019","article-title":"beta2-integrin LFA1 mediates airway damage following neutrophil transepithelial migration during respiratory syncytial virus infection","volume":"56","author":"Herbert","year":"2020","journal-title":"Eur Respir J"},{"key":"B56","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02161-19","article-title":"Neutrophil-airway epithelial interactions result in increased epithelial damage and viral clearance during respiratory syncytial virus infection","volume-title":"J Virol.","author":"Deng","year":"2020"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.cmi.2020.07.024","article-title":"Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain","volume":"26","author":"Berenguer","year":"2020","journal-title":"Clin Microbiol Infect."},{"key":"B58","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1165\/rcmb.2003-0136OC","article-title":"Apoptosis and necrosis induced by cyclic mechanical stretching in alveolar type II cells","volume":"30","author":"Hammerschmidt","year":"2004","journal-title":"Am J Respir Cell Mol Biol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1038\/s41598-018-21073-x","article-title":"Hypoxia induces pulmonary fibroblast proliferation through NFAT signaling","volume":"8","author":"Senavirathna","year":"2018","journal-title":"Sci Rep."},{"key":"B60","article-title":"SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis","volume-title":"Cell.","author":"Wendisch","year":"2021"},{"key":"B61","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/cphy.c190017","article-title":"Oxidative stress in pulmonary fibrosis","volume":"10","author":"Otoupalova","year":"2020","journal-title":"Compr Physiol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"14532","DOI":"10.1038\/ncomms14532","article-title":"Cellular senescence mediates fibrotic pulmonary disease","volume":"8","author":"Schafer","year":"2017","journal-title":"Nat Commun."},{"key":"B63","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1172\/JCI93557","article-title":"Extracellular matrix as a driver of progressive fibrosis","volume":"128","author":"Herrera","year":"2018","journal-title":"J Clin Invest."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.3390\/jcm9061917","article-title":"COVID-19: the potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection","volume":"9","author":"Lechowicz","year":"2020","journal-title":"J Clin Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2\u2014preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med."},{"key":"B67","doi-asserted-by":"crossref","DOI":"10.1007\/s00467-022-05681-4","article-title":"child with crescentic glomerulonephritis following SARS-CoV-2 mRNA (Pfizer-BioNTech) vaccination","volume-title":"Pediatr Nephrol.","author":"Kim","year":"2022"},{"key":"B68","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01822-22","article-title":"A bacteriophage-based, highly efficacious, needle- and adjuvant-free, mucosal COVID-19 vaccine","volume-title":"mBio","author":"Zhu","year":""},{"key":"B69","doi-asserted-by":"publisher","first-page":"2090176","DOI":"10.1080\/21645515.2022.2090176","article-title":"Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study","volume":"2022","author":"Zeng","year":"2022","journal-title":"Human Vaccines Immunotherap"},{"key":"B70","doi-asserted-by":"publisher","first-page":"ofac178","DOI":"10.1093\/ofid\/ofac178","article-title":"SARS-CoV-2 mRNA vaccine effectiveness in health care workers by dosing interval and time since vaccination: test-negative design, British Columbia, Canada","volume":"9","author":"El Adam","year":"2022","journal-title":"Open Forum Infect Dis."},{"key":"B71","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3390\/vaccines10070985","article-title":"Systematic review on pathophysiological complications in severe COVID-19 among the non-vaccinated and vaccinated population","volume":"10","author":"Rabaan","year":"2022","journal-title":"Vaccines"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.967829\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T05:31:26Z","timestamp":1663651886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.967829\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":71,"alternative-id":["10.3389\/fpubh.2022.967829"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.967829","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]},"article-number":"967829"}}